Finally! The extension studies of the phase 3 alemtuzumab trials, 11–13 years after first prescribing alemtuzumab or interferon-beta The main take-aways are that 30-50% of people needed no futher treatment and no new safety concern emerged
journals.sagepub.com/doi/10.…
Novel paraneoplastic mechanism for cerebellar ataxia in Erdheim-Chester disease casereports.bmj.com/content/…
Another nice paper on MOG from Tohoku University. 15% of people with #MOGAD have MOG Abs only detectable in the CSF; these are most likely in cases of cortical encephalitis and least in optic neuritis.doi.org/10.1093/brain/awad12…
@Brain1878
#MOG
Cambridge Clinical MS Research retweeted
fascinating, if counterintuitive finding: myelin encapsulating axons actually *increase* the risk of axon degeneration in multiple sclerosis
what implications for remyelination therapies for MS? seems timing of therapy in demyel course might be critical
nature.com/articles/s41593-0…
Cambridge Clinical MS Research retweeted
Singapore researchers plan to organize preclinical studies aimed at studying dietary omega-3 and its effects on remyelination. buff.ly/3N6jhxr
#multiplesclerosis #msnews #msawareness #mscommunity
Compulsory reading for all clinical trialists in the UK. An accurate description of the problems we face..... Lets hope someone takes notice.
#oshaughnessyreport
#clinicaltrials
@Cambridge_Uni
@nihrbrccam
gov.uk/government/publicatio…
A big #WorldMSDay today!
Today is #WorldMSDay and this year's theme is #MSConnections.
Today, we'll be raising awareness of MS and sharing just some of the ways our community is providing support and helping people affected by MS to connect. 🧡
Join us in raising awareness - RT to spread the word!
Cambridge Clinical MS Research retweeted
Impressive multi-omics and human iNSC modeling work to study senescence in progressive multiple sclerosis by @Pluchinolab at #KSNeuroimmune23 @KeystoneSymp !
** final reminder ** to register for the Cambridge Centre for Myelin Repair (CCMR)’s 2nd Annual Symposium.
Free to people affected by MS
Register here: https://teapawt.net/t.co/O2EJaEhT7a
Cambridge Clinical MS Research retweeted
Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis | Science Advances science.org/doi/10.1126/scia…
One week to go! The Annual CCMR symposium for everyone interested in myelin repair: biologists, clinicians and people affected by multiple sclerosis
Replying to @CentreMyelin
Would you like to join, but you're not in Cambridge? No problem - register for virtual attendance. 🖥️
Calling all scientists interested to what it is like to have #MS
What question would you like me to put to our community of people with MS #pwMS in the CCMR symposium?
Reply here or DM
@CentreMyelin
@mssocietyuk
@MStranslate
@MSTrust
@CamNeuro
@Pluchinolab
@Cambridge_Uni
MWF of the corpus callosum is a robust measure of remyelination: Results from the ReBUILD trial | Proceedings of the National Academy of Sciences pnas.org/doi/10.1073/pnas.22…
2
199
It's here!
Cambridge Centre for Myelin Repair Annual Symposium.
25-26 May 2023
Bruno Stankoff (Paris),
Rosa Chiara Paolicelli (Lausanne)
David Lyons (Edinburgh) with a garden party, food, drinks and music. Book here
https://teapawt.net/t.co/O2EJaEhT7a
@CentreMyelin
@CamNeuro
Cambridge Clinical MS Research retweeted
📢Registration now open for our second annual symposium on 25-26 May!
💥A jam-packed lineup of exciting talks from early career researchers, neuroscientists, clinicians and other experts.
✉️We invite people affected by MS to join the conversation on the afternoon of Fri 26 May
Cambridge Clinical MS Research retweeted
How can advanced neuroimaging be used to help understand Parkinson’s disease dementia?
Find out in this latest edition of our ‘Behind the Research’ newsletter ⤵️
linkedin.com/pulse/how-can-w…
In vivo MRI is sensitive to remyelination in a nonhuman primate model of multiple sclerosis doi.org/10.7554/eLife.73786
2
206
Our annual symposium! Save the date for an in-person or on-line feast of myelin research!
@CentreMyelin @mssocietyuk @NMSS_Aus #myelin #remyelination
Cambridge Clinical MS Research retweeted
Lesional Antibody Synthesis and Complement Deposition Associate With De Novo Antineuronal Antibody Synthesis After Spinal Cord Injury: https://teapawt.net/t.co/GHSNJf237Y
#NeuroTwitter
Cambridge Clinical MS Research retweeted
Remyelination by surviving oligodendrocytes is inefficient in the inflamed mammalian cortex
Remyelination therapies do not boost the contribution of surviving oligodendrocytes @NeuroCellPress
cell.com/neuron/fulltext/S08…




















